Medtronic, Inc. Touts Endurant Stent Graft Data

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Medtronic touts positive data from a pair of clinical trials for its Endurant stent graft for treating abdominal aortic aneurysms. Medtronic (NYSE:MDT) said data from a pair of clinical trials evaluating its Endurant stent graft for abdominal aortic aneurysms "affirm the Endurant stent graft's durable, consistent and proven outcomes." The data, from the independent Pandora study and the Medtronic-sponsored Engage trial, showed low rates of "aneurysm-related" mortality, reintervention, stent graft migration and conversion to open surgery, according to a press release.

Help employers find you! Check out all the jobs and post your resume.

Back to news